Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Sergio Chiarella

Allergy & Immunology Rochester, MN Medical Doctor

NPI 1295020550 CMS profile 884329

200 1St St Sw, Rochester, MN 55905

Open in the dashboard

General payments

$1,457

5 records reported · program years 2019–2025

Research payments

$2,128

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$58,430 paid to institutions, not to them · program years 2021–2025

Through program year 2025, Sergio Chiarella of Rochester, MN is reported in the CMS Open Payments database as having received $1,457 across 5 general payments and $2,128 in research payments paid to them. Separately, studies naming them as principal investigator received $58,430 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 51st percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $524 2
2024 General $875 1
2023 Research $2,128 2
2022 General $23 1
2019 General $35 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sergio Chiarella
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Sergio Chiarella were reported at $524. Among 2,466 Allergy & Immunology profiles paid that year, the median was $1,140 and the middle half received between $272 and $2,892.

Show as a table
Year Sergio Chiarella Allergy & Immunology median Middle half National median
2019 $35 $594 $163–$1,512 $163
2020 $0 $426 $106–$1,233 $114
2021 $0 $638 $157–$1,708 $132
2022 $23 $790 $205–$1,961 $149
2023 $0 $852 $220–$2,147 $160
2024 $875 $865 $203–$2,267 $164
2025 $524 $1,140 $272–$2,892 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merck Sharp & Dohme Corporation $1,250 2 payments
  2. BioCryst US Sales Co., LLC $149 1 payment
  3. Novartis Pharmaceuticals Corporation $35 1 payment
  4. Incyte Corporation $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $1,250 2 payments
  2. Food and Beverage $207 3 payments
Products named General payments · program years 2019–2025
  1. Orladeyo $149 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. F. Hoffmann-La Roche AG $2,128 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

42

Median for Allergy/ Immunology: 449

Drug cost

$8,947

Median for Allergy/ Immunology: $169,700

Branded share of claims

50%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Breo Ellipta Fluticasone/Vilanterol Brand 21 $8,793
Montelukast Sodium Generic 21 $154

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 20 billing codes

Paid by Medicare

$9,610

Medicare's payments for the services billed

Medicare patients

80

Average age 70

Services billed

590

47 women, 33 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 61%
Arthritis 50%
Depression 26%
Cancer 25%
Ischemic heart disease 21%
Chronic kidney disease 21%
Osteoporosis 18%
Atrial fibrillation 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

7 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Minnesota

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record